Raphael E. Szalat, MD, PhD

Assistant Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

I received my medical training at the University of Pierre and Marie Curie, in Paris, France. After Internal Medicine residency, I specialized in Immunology and plasma cell disorders including multiple myeloma and monoclonal gammopathies of clinical significance and became a clinical assistant professor in the department of Immuno-Hematology in Saint-Louis hospital, Paris. I next completed a PhD and post-doc in hematology studying genomics in Multiple Myeloma at the Dana-Farber Cancer Institute, Harvard Medical School in collaboration with La Sorbonne University, Paris and a clinical fellowship in Hematology and Oncology at the Boston University Medical Center. I am currently the multiple myeloma program director and the Stem Cell Transplant director at the Boston University Medical Center. My main interests are to develop myeloma clinical trials and to perform basic and translational research on multiple myeloma and other plasma cell disorders including AL amyloidosis and other monoclonal gammopathy of clinical significance.

Publications

  • Published 3/29/2026

    George T, Staron A, Burks EJ, Szalat RE, Sanchorawala V. Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis. Br J Haematol. 2026 Mar 29. PMID: 41905782.

    Read at: PubMed

  • Published 1/15/2026

    Muchtar E, Palladini G, Schonland S, Geyer S, Dooley KE, Dispenzieri A, Wisniowski B, Merlini G, Milani P, Hegenbart U, Dittrich T, Kastritis E, Dimopoulos MA, Sanchorawala V, Szalat R, Liedtke M, Gupta M, Landau H, Lentzsch S, Hughes MS, Cibeira MT, Blade J, Kumar SK, Wechalekar A, Gertz MA. Hepatic response criteria in light chain amyloidosis: a multicenter validation study. Haematologica. 2026 Jan 15. PMID: 41537335.

    Read at: PubMed

  • Published 1/12/2026

    Fulciniti M, Yao Y, Perini T, Fong Ng J, Schavgoulidze A, Deng S, Cui J, Encinas Mayoral J, Ladisa F, Young RM, Epstein CB, White CM, Ott CJ, Gulla A, Matulis SM, Sperling AS, Morelli E, Boise LH, Binder M, Szalat R, Samur MK, Anderson KC, Munshi NC. ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. Blood Cancer Discov. 2026 Jan 12; 7(1):129-141. PMID: 41104834.

    Read at: PubMed

  • Published 12/12/2025

    Ferri GM, Martinez CB, Acevedo J, Bhatt S, Verma KP, Lee J, Abdallah M, Szalat RE, Sloan JM. Exploring the effect of Duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors. Breast Cancer Res Treat. 2025 Dec 12; 215(1):36. PMID: 41385110.

    Read at: PubMed

  • Published 12/11/2025

    Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK. Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. J Clin Oncol. 2026 Feb; 44(4):321-334. PMID: 41380103.

    Read at: PubMed

View All 66 Publications:   View Full Profile in BUMC

Websites

Education

  • Université Paris-Sorbonne, Paris IV, MD
  • Université Paris-Sorbonne, Paris IV, PhD

View all profiles